{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:40:08Z","timestamp":1792456808184,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Yttrium-90 transarterial radioembolization (TARE) combined with immune checkpoint inhibitors has been investigated as a potential therapeutic strategy for advanced hepatocellular carcinoma (HCC); however, evidence supporting its addition to current standard systemic therapy remains limited. We aimed to compare clinical outcomes in patients with advanced HCC treated with TARE followed by atezolizumab plus bevacizumab (TARE\u2013Atezo\/Bev) and Atezo\/Bev alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included systemic therapy-na\u00efve patients with advanced HCC treated with Atezo\/Bev alone or TARE\u2013Atezo\/Bev at a single tertiary hospital between 2018 and 2025. Baseline characteristics were adjusted using propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 156 eligible patients were enrolled, including 93 in the Atezo\/Bev group and 63 in the TARE\u2013Atezo\/Bev group. In the unmatched cohort, median OS was significantly longer in the TARE\u2013Atezo\/Bev group than in the Atezo\/Bev group (14.1 vs 6.4 months; hazard ratio=0.43, 95% confidence interval\u2009=\u20090.29\u20130.63;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with consistent results after PSM (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) and IPTW (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Although PFS was comparable between groups in the overall cohort, patients with Child\u2013Pugh class A (OS: 14.6 vs 7.1 months; PFS: 7.7 vs 6.3 months) or ALBI grade 1 (OS: 21.4 vs 8.3 months; PFS: 8.1 vs 5.7 months) had significantly longer OS and PFS in the TARE\u2013Atezo\/Bev group, with similar results after adjustment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sequential TARE\u2013Atezo\/Bev may improve survival compared with Atezo\/Bev alone in patients with advanced HCC and well-preserved liver function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>The survival benefit of yttrium-90 TARE followed by Atezo\/Bev compared with Atezo\/Bev alone remains uncertain given limited evidence in advanced HCC<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>TARE followed by Atezo\/Bev was associated with significantly longer OS than Atezo\/Bev alone, with both OS and PFS improved in patients with advanced HCC and preserved liver function<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Sequential TARE followed by Atezo\/Bev may offer a survival advantage in selected patients with advanced HCC, supporting the integration of locoregional and systemic therapies<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-026-12876-y","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:52:53Z","timestamp":1792410773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential transarterial radioembolization and atezolizumab plus bevacizumab improves survival in advanced hepatocellular carcinoma"],"prefix":"10.1007","author":[{"given":"Yunmi","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Haeng","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeayeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ju","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9141-7773","authenticated-orcid":false,"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"12876_CR1","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Danpanichkul P, Agopian V et al (2025) Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol 31:S228\u2013S254","journal-title":"Clin Mol Hepatol"},{"key":"12876_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905","journal-title":"N Engl J Med"},{"key":"12876_CR3","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1:EVIDoa2100070","journal-title":"NEJM Evid"},{"key":"12876_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.17998\/jlc.2022.01.16","volume":"22","author":"JW Choi","year":"2022","unstructured":"Choi JW, Kim HC (2022) Radioembolization for hepatocellular carcinoma: what clinicians need to know. J Liver Cancer 22:4\u201313","journal-title":"J Liver Cancer"},{"key":"12876_CR5","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E et al (2021) Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 74:2342\u20132352","journal-title":"Hepatology"},{"key":"12876_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","volume":"7","author":"E Kim","year":"2022","unstructured":"Kim E, Sher A, Abboud G et al (2022) Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol 7:843\u2013850","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"12876_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497\u2013507.e2","journal-title":"Gastroenterology"},{"key":"12876_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.diii.2025.09.002","volume":"107","author":"Y Park","year":"2026","unstructured":"Park Y, Cho Y, Kim SU et al (2026) Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis. Diagn Interv Imaging 107:25\u201337","journal-title":"Diagn Interv Imaging"},{"key":"12876_CR9","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.3350\/cmh.2024.0832","volume":"31","author":"H Li","year":"2025","unstructured":"Li H, Lu H, Shen XP, Li XS (2025) Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 31:e3\u2013e4","journal-title":"Clin Mol Hepatol"},{"key":"12876_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2967\/jnumed.114.145177","volume":"56","author":"E Garin","year":"2015","unstructured":"Garin E, Rolland Y, Edeline J et al (2015) Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med 56:339\u2013346","journal-title":"J Nucl Med"},{"key":"12876_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, Kudo M, Erinjeri JP et al (2025) Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 405:216\u2013232","journal-title":"Lancet"},{"key":"12876_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y et al (2025) Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet 405:203\u2013215","journal-title":"Lancet"},{"key":"12876_CR13","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"M Seidensticker","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H et al (2019) Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 71:1164\u20131174","journal-title":"J Hepatol"},{"key":"12876_CR14","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","volume":"6","author":"D Tai","year":"2021","unstructured":"Tai D, Loke K, Gogna A et al (2021) Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol 6:1025\u20131035","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"12876_CR15","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.14309\/ajg.0000000000002467","volume":"118","author":"YH Yeo","year":"2023","unstructured":"Yeo YH, Liang J, Lauzon M et al (2023) Immunotherapy and transarterial radioembolization combination treatment for advanced hepatocellular carcinoma. Am J Gastroenterol 118:2201\u20132211","journal-title":"Am J Gastroenterol"},{"key":"12876_CR16","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.3390\/cancers17172745","volume":"17","author":"KG N\u00fa\u00f1ez","year":"2025","unstructured":"N\u00fa\u00f1ez KG, Sandow T, Grahovac A et al (2025) Contemporary clinical utilization of radioembolization with immune checkpoint inhibitors as first-line treatment in HCC: real-world report on safety and outcomes. Cancers (Basel) 17:2745","journal-title":"Cancers (Basel)"},{"key":"12876_CR17","first-page":"187","volume":"6","author":"Q Yu","year":"2023","unstructured":"Yu Q, Wang Y, Ungchusri E et al (2023) Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: a preliminary report of safety and feasibility. J Interv Med 6:187\u2013193","journal-title":"J Interv Med"},{"key":"12876_CR18","doi-asserted-by":"publisher","first-page":"TPS622","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS622","volume":"41","author":"AR He","year":"2023","unstructured":"He AR, Toskich B (2023) The ROWAN study: safety and efficacy of transarterial radioembolization with Y-90 glass microspheres and the STRIDE regimen in hepatocellular carcinoma. J Clin Oncol 41:TPS622\u2013TPS622","journal-title":"J Clin Oncol"},{"key":"12876_CR19","doi-asserted-by":"publisher","first-page":"TPS358","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS358","volume":"39","author":"AR He","year":"2021","unstructured":"He AR, Kim AY, Toskich BM et al (2021) A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC). J Clin Oncol 39:TPS358\u2013TPS358","journal-title":"J Clin Oncol"},{"key":"12876_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","volume":"84","author":"M Reig","year":"2026","unstructured":"Reig M, Sanduzzi-Zamparelli M, Forner A et al (2026) BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update. J Hepatol 84:631\u2013654","journal-title":"J Hepatol"},{"key":"12876_CR21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","volume":"25","author":"YS Chun","year":"2018","unstructured":"Chun YS, Pawlik TM, Vauthey J-N (2018) 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 25:845\u2013847","journal-title":"Ann Surg Oncol"},{"key":"12876_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/BF02471576","volume":"19","author":"Liver Cancer Study Group of Japan","year":"1989","unstructured":"Liver Cancer Study Group of Japan (1989) The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 19:98\u2013129.","journal-title":"Jpn J Surg"},{"key":"12876_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jvir.2010.10.029","volume":"22","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Gates VL et al (2011) Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 22:265\u2013278","journal-title":"J Vasc Interv Radiol"},{"key":"12876_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360","journal-title":"Semin Liver Dis"},{"key":"12876_CR25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41417-024-00764-w","volume":"31","author":"F Safri","year":"2024","unstructured":"Safri F, Nguyen R, Zerehpooshnesfchi S, George J, Qiao L (2024) Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications. Cancer Gene Ther 31:1105\u20131112","journal-title":"Cancer Gene Ther"},{"key":"12876_CR26","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jvir.2024.11.012","volume":"36","author":"CD Malone","year":"2025","unstructured":"Malone CD, Bajaj S, He A et al (2025) Combining radioembolization and immune checkpoint inhibitors for the treatment of hepatocellular carcinoma: the quest for synergy. J Vasc Interv Radiol 36:414\u2013424.e2","journal-title":"J Vasc Interv Radiol"},{"key":"12876_CR27","doi-asserted-by":"publisher","first-page":"41242","DOI":"10.18632\/oncotarget.17168","volume":"8","author":"KJ Kim","year":"2017","unstructured":"Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J (2017) Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget 8:41242\u201341255","journal-title":"Oncotarget"},{"key":"12876_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","volume":"68","author":"V Chew","year":"2019","unstructured":"Chew V, Lee YH, Pan L et al (2019) Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 68:335\u2013346","journal-title":"Gut"},{"key":"12876_CR29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/gutjnl-2021-326869","volume":"72","author":"L Rivoltini","year":"2023","unstructured":"Rivoltini L, Bhoori S, Camisaschi C et al (2023) Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers. Gut 72:406\u2013407","journal-title":"Gut"},{"key":"12876_CR30","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","volume":"55","author":"Y Choi","year":"2023","unstructured":"Choi Y, Jung K (2023) Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med 55:2308\u20132319","journal-title":"Exp Mol Med"},{"key":"12876_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ijrobp.2020.12.031","volume":"110","author":"JH Park","year":"2021","unstructured":"Park JH, Kim HY, Lee A et al (2021) Enlightening the immune mechanism of the abscopal effect in a murine HCC model and overcoming the late resistance with anti-PD-L1. Int J Radiat Oncol Biol Phys 110:510\u2013520","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"12876_CR32","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","volume":"29","author":"YB Lee","year":"2023","unstructured":"Lee YB, Nam JY, Cho EJ et al (2023) A phase I\/IIa trial of Yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma. Clin Cancer Res 29:3650\u20133658","journal-title":"Clin Cancer Res"},{"key":"12876_CR33","doi-asserted-by":"publisher","first-page":"e007106","DOI":"10.1136\/jitc-2023-007106","volume":"11","author":"NA Kaya","year":"2023","unstructured":"Kaya NA, Tai D, Lim X et al (2023) Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma. J Immunother Cancer 11:e007106","journal-title":"J Immunother Cancer"},{"key":"12876_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12029-025-01189-w","volume":"56","author":"S Hosseini Shabanan","year":"2025","unstructured":"Hosseini Shabanan S, Shobeiri P, Behnoush AH, Haghshomar M, Fowler KJ, Lewandowski RJ (2025) 90Y-transarterial radioembolization combined with immune checkpoint inhibitors in hepatocellular carcinoma: a systematic review. J Gastrointest Cancer 56:73","journal-title":"J Gastrointest Cancer"},{"key":"12876_CR35","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00330-025-11882-w","volume":"36","author":"JW Choi","year":"2026","unstructured":"Choi JW, Suh M, Choi Y, Lee M, Paeng JC, Kim HC (2026) Yttrium-90 glass microsphere radioembolization as frontline treatment for hepatocellular carcinoma with localized portal vein invasion. Eur Radiol 36:743\u2013753","journal-title":"Eur Radiol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12876-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12876-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12876-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:03:16Z","timestamp":1792454596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12876-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":35,"alternative-id":["12876"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12876-y","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific guarantor of this publication is Yoon Jun Kim.","order":1,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J.W.C. reports receiving honoraria from Boston Scientific, SIRTEX, Guerbet, Terumo, and Nextbiomedical, research funding from Boston Scientific, Guerbet, and Nextbiomedical, and travel support from SIRTEX and Nextbiomedical. Y.B.L. reports receiving research grants from Samjin Pharmaceuticals and Yuhan Pharmaceuticals. J.-H.L. reports receiving research grants from Yuhan Pharmaceuticals, and lecture fees from GC Cell, Daewoong Pharmaceuticals, Samil Pharmaceutical, and Gilead Korea. S.J.Y. reports receiving research grants from Yuhan Pharmaceuticals and Daewoong Pharmaceuticals. H.-C.K. reports receiving honoraria from Boston Scientific, SIRTEX, and Guerbet, and research funding and travel support from SIRTEX. J.-H.Y. reports receiving research grants from Dicerna Pharmaceuticals, Roche, GlaxoSmithKline, AstraZeneca, Daewoong Pharmaceuticals, and Hanmi Pharmaceuticals. Y.J.K. reports receiving research grants from Boston Scientific, AstraZeneca, Samjin, Daewoong, Yuhan, and Boryung. Y.K., H.S., M.H.H., J.P., and E.J.C. have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"One of the authors has significant statistical expertise.","order":3,"name":"Ethics","label":"Statistics and biometry","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was approved by the Institutional Review Board of SNUH (No. E-2510-015-1681).","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Study subjects or cohorts overlap","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"order":7,"name":"Ethics","label":"Methodology","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}